Advertisement

Psychopharmacology

, Volume 172, Issue 2, pp 145–156 | Cite as

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study

  • Felix Hasler
  • Ulrike Grimberg
  • Marco A. Benz
  • Theo Huber
  • Franz X. Vollenweider
Original Investigation

Abstract

Rationale

Serotonin (5-Hydroxytryptamine, 5-HT) receptors play an important role in perception, affect regulation and attention. Pharmacological challenge with the 5-HT2A agonist psilocybin (PY) is useful in studying the neurobiological basis of cognition and consciousness.

Objective

Investigation of dose-dependent effects of PY on psycho(patho)logical and physiological parameters.

Methods

Eight subjects received placebo (PL), and 45 (“very low dose, VLD”), 115 (“low dose, LD”), 215 (“medium dose, MD”), and 315 (“high dose, HD”) μg/kg body weight PY. The “Altered States of Consciousness Rating Scale” (5D-ASC), the “Frankfurt Attention Inventory” (FAIR), and the “Adjective Mood Rating Scale” (AMRS) were used to assess the effects of PY on psycho(patho)logical core dimensions, attention, and mood. A 24-h electrocardiogram (EKG) was recorded and blood pressure was measured. Plasma concentrations of thyroid-stimulating hormone (TSH), prolactin (PRL), cortisol (CORT), adrenocorticotropic hormone (ACTH), and standard clinical chemical parameters were determined.

Results

PY dose dependently increased scores of all 5D-ASC core dimensions. Only one subject reacted with transient anxiety to HD PY. Compared with PL, MD and HD PY led to a 50% reduction of performance in the FAIR test. “General inactivation”, “emotional excitability”, and “dreaminess” were the only domains of the AMRS showing increased scores following MD and HD PY. The mean arterial blood pressure (MAP) was moderately elevated only 60 min following administration of HD PY. Neither EKG nor body temperature was affected by any dose of PY. TSH, ACTH, and CORT plasma levels were elevated during peak effects of HD PY, whereas PRL plasma levels were increased following MD and HD PY.

Conclusion

PY affects core dimensions of altered states of consciousness and physiological parameters in a dose-dependent manner. Our study provided no cause for concern that PY is hazardous with respect to somatic health.

Keywords

Psilocybin Dose–effect study Psycho(patho)logy Neuroendocrinology Cardiovascular effects Altered states of consciousness 

Notes

Acknowledgements

The authors thank Drs Dieter Vonderschmitt, Arnold von Eckardstein, and Kathrin Rentsch, Institute of Clinical Chemistry of the University of Zürich, for analysis of hormones and clinical-chemical parameters, and Martin Dobricki for assistance during the experimental part of the study. The authors especially thank Drs Stephan Ludewig, David Nichols, George Greer, and Francisco Moreno for critical comments on the manuscript. This investigation was financially supported by the Heffter Research Institute, Santa Fe, New Mexico, USA, and the Swiss Federal Office for Public Health (BAG grant no. 00.001023).

References

  1. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23SCrossRefPubMedGoogle Scholar
  2. Bonini P, Ceriotti F, Keller F, Brauer P, Stolz H, Pascual C, Garcia-Beltran L, Vonderschmitt DJ, Pei P (1992) Multicentre evaluation of the Boehringer Mannheim/Hitachi 747 analysis system. Eur J Clin Chem Clin Biochem 30:881–899PubMedGoogle Scholar
  3. Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210–221PubMedGoogle Scholar
  4. Creese I, Burt DR, Snyder SH (1975) The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 17:1715–1719CrossRefPubMedGoogle Scholar
  5. Cuomo MJ, Dyment PG, Gammino VM (1994) Increasing use of ‘ecstasy’ (MDMA) and other hallucinogens on a college campus. Am College Health 42:271–274Google Scholar
  6. Derogatis LR, Lipman RS, Covi L (1973) SCL-90: an outpatient psychiatric rating scale—preliminary report. Psychopharm Bull 9:13–28Google Scholar
  7. Dittrich A (1993) Psychological aspects of altered states of consciousness of the LSD type: measurement of their basic dimensions and prediction of individual differences. In: Pletscher A, Ladewig D (eds) Fifty years of LSD. Current status and perspectives of hallucinogens. Parthenon, New York, pp 101–118Google Scholar
  8. Dittrich A (1996) Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. VWB Verlag, BerlinGoogle Scholar
  9. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychology 31:80–84Google Scholar
  10. Dittrich A, Lamparter D, Maurer M (1999) 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung. PSIN Plus, ZürichGoogle Scholar
  11. Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA, Macher JP (1999) Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 24:695–712CrossRefPubMedGoogle Scholar
  12. Ellis KA, Nathan PJ (2001) The pharmacology of human working memory. Int J Neuropsychopharmacol 4:299–313CrossRefPubMedGoogle Scholar
  13. Fahrenberg J, Hampel R, Selg H (1984) Das Freiburger Persönlichkeitsinventar FPI. D-Göttingen, HogrefeGoogle Scholar
  14. Fried R (2000) Aspartatamino-transferase (AST, ASAT, GOT) im Plasma. Manual of the Institute of Clinical Chemistry of the University Hospital of Zürich. ZürichGoogle Scholar
  15. Fuller RW (1981) Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32:118–127PubMedGoogle Scholar
  16. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA (1998) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 9:561–566PubMedGoogle Scholar
  17. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methlyenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 142:41–50PubMedGoogle Scholar
  18. Hasler F (1997) Untersuchungen zur Humanpharmakokinetik von Psilocybin. Thesis, University of BernGoogle Scholar
  19. Hasler F, Bourquin D, Brenneisen R, Baer T, Vollenweider FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72:175–184CrossRefPubMedGoogle Scholar
  20. Hollister LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130:42–53PubMedGoogle Scholar
  21. Holmes MC, DiRenzo GD, Beckford B, Gillham B, Jones MT (1982) Role of serotonin in the control of secretion of corticotropin releasing factor. J Endocrinol 93:151–160PubMedGoogle Scholar
  22. Isbell H (1959) Comparison of reactions induced by psilocybin and LSD-25 in man. Psychopharmacology 1:29–38Google Scholar
  23. Janke W, Debus G (1978) Die Eigenschaftswörterliste (EWL-K)—Ein Verfahren zur Erfassung der Befindlichkeit. Hogrefe, GöttingenGoogle Scholar
  24. Kapur S, Remington G (1996) Serotonin–dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476PubMedGoogle Scholar
  25. Knedel M, Haeckel R, Seidel D, Thiery J, Vonderschmitt DJ, Haenseler E (1986) Analytical performance of the random access analyser Hitachi 737. A multicentre evaluation. J Clin Chem Clin Biochem 24:409–432PubMedGoogle Scholar
  26. Krulich L (1982) Neurotransmitter control of thyrotropin secretion. Neuroendocrinology 35:139–147PubMedGoogle Scholar
  27. Laux L, Glanzmann P, Schaffner P, Spielberger CD (1981) Das State-Trait-Angstinventar (STAI). Beltz, WeinheimGoogle Scholar
  28. Lindenblatt H, Kraemer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar KA (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid–liquid extraction with automated on-line solid-phase extraction. J Chromatogr B 709:255–263CrossRefGoogle Scholar
  29. Lohrer F, Albers M (1999) Biological drugs—is there a change in substance abuse? Psychiatr Prax 26:199–201Google Scholar
  30. Mannisto PT (1983) Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress. Med Biol 61:92–100PubMedGoogle Scholar
  31. Marek GJ, Aghajanian GK (1998) Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend 51:189–198PubMedGoogle Scholar
  32. McKenna DJ, Repke DB, Lo L, Peroutka SJ (1990) Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29:193–198CrossRefPubMedGoogle Scholar
  33. Meltzer HY, Nash JF (1988) Serotonin and mood: neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Neuroendocrinology of mood. Springer, Berlin Heidelberg New York, pp 183–210Google Scholar
  34. Meneses A (1998) Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Rev Neurosci 4:275–289Google Scholar
  35. Mitsuma T, Nogimori T (1983) Effects of serotonergic system on hypothalamic–pituitary–thyroid axis in rats. Horm Metab Res 15:346–349PubMedGoogle Scholar
  36. Moosbrugger H, Oehlschlägel J (1996) FAIR Frankfurter Aufmerksamkeitsinventar. Testmanual, Hans Huber, GöttingenGoogle Scholar
  37. O’Malley BP, Jennings PE, Cook N, Barnett DB, Rosenthal FD (1984) The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor). Psychoneuroendocrinology 9:13–19CrossRefPubMedGoogle Scholar
  38. Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357–364CrossRefGoogle Scholar
  39. Prescott RW, Kendall-Taylor P, Weightman DR, Watson MJ, Ratcliffe WA (1984) The effect of ketanserin, a specific serotonin antagonist on the PRL, HG, ACTH and cortisol response to hypoglycaemia in normal subjects. Clin Endocrinol 20:137–142Google Scholar
  40. Ramage AG (2001) Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res Bull 56:425–439CrossRefPubMedGoogle Scholar
  41. Robinson AG, Nelson PB (1983) Prolactinomas in women: current therapies. Ann Int Med 99:115–118PubMedGoogle Scholar
  42. Scharfetter C (1981) Ego-psychopathology: the concept and its empirical evaluation. Psychol Med 11:273–280PubMedGoogle Scholar
  43. Silva JD, Nunes MT (1996) Facilitatory role of serotonin (5-HT) in the control of thyrotropin releasing hormone/throtropin (TRH/TSH) secretion in rats. Braz J Med Biol Res 29:677–683PubMedGoogle Scholar
  44. Strassman RJ, Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 51:85–97PubMedGoogle Scholar
  45. Supprian T, Supprian R, Rosler M, Wanke K (2001) Psychoactive mushrooms—an update. Fortschr Neurol Psychiatr 69:597–602CrossRefPubMedGoogle Scholar
  46. Van de Kar LD, Karteszi M, Bethea CL, Ganong WF (1985) Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 41:380–384PubMedGoogle Scholar
  47. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Thackery SG (2001) 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21:3572–3579PubMedGoogle Scholar
  48. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495–507CrossRefPubMedGoogle Scholar
  49. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357–372Google Scholar
  50. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport 9:3897–3902PubMedGoogle Scholar
  51. Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with (11C)raclopride. Neuropsychopharmacology 20:424–433Google Scholar
  52. Williams GV, Rao SG, Goldman-Rakic PS (2002) The physiological role of 5-HT2A receptors in working memory. J Neurosci 22:2843–2854PubMedGoogle Scholar
  53. Wittchen HU, Pfister H (1997) DIA-X-Interview. Swet Test Services, FrankfurtGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Felix Hasler
    • 1
  • Ulrike Grimberg
    • 1
  • Marco A. Benz
    • 1
  • Theo Huber
    • 1
  • Franz X. Vollenweider
    • 1
  1. 1.Heffter Research CenterPsychiatric University Hospital ZürichZürichSwitzerland

Personalised recommendations